Details

Autor(en) / Beteiligte

• Gharpure, Kshipra M
• Lara, Olivia D
• Wen, Yunfei
• Pradeep, Sunila
• LaFargue, Chris
• Ivan, Cristina
• Rupaimoole, Rajesha
• Hu, Wei
• Mangala, Lingegowda S
• Wu, Sherry Y
• Nagaraja, Archana S
• Baggerly, Keith
• Sood, Anil K

Titel

ADH1B promotes mesothelial clearance and ovarian cancer infiltration

Ist Teil von

• Oncotarget, 2018-05, Vol.9 (38), p.25115-25126

Ort / Verlag

United States: Impact Journals LLC

Erscheinungsjahr

2018

Link zum Volltext

Quelle

EZB Free E-Journals

Beschreibungen/Notizen

• Primary debulking surgery followed by adjuvant chemotherapy is the standard treatment for ovarian cancer. Residual disease after primary surgery is associated with poor patient outcome. Previously, we discovered ADH1B to be a molecular biomarker of residual disease. In the current study, we investigated the functional role of ADH1B in promoting ovarian cancer cell invasiveness and contributing to residual disease. We discovered that ADH1B overexpression leads to a more infiltrative cancer cell phenotype, promotes metastasis, increases the adhesion of cancer cells to mesothelial cells, and increases extracellular matrix degradation. Live cell imaging revealed that ADH1B-overexpressing cancer cells efficiently cleared the mesothelial cell layer compared to control cells. Moreover, gene array analysis revealed that ADH1B affects several pathways related to the migration and invasion of cancer cells. We also discovered that hypoxia increases ADH1B expression in ovarian cancer cells. Collectively, these findings indicate that ADH1B plays an important role in the pathways that promote ovarian cancer cell infiltration and may increase the likelihood of residual disease following surgery.